Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 15/20 | 0.53 |
| ▸ | RAF1 | P04049 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | FPR2 | P25090 | 3/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29757282 | 1.00 | P2RX3 (0.53) | P2RX3SCN9ARAF1HRH3FPR2 | |
| SCHEMBL2427202 | 0.86 | P2RX3 (0.52) | P2RX3SCN9ARAF1HRH3GRM5 | |
| SCHEMBL4369342 | 0.86 | PARP10 (0.54) | P2RX3RAF1 | |
| SCHEMBL177841 | 0.86 | PARP10 (0.54) | P2RX3RAF1 | |
| SCHEMBL23900346 | 0.85 | USP2 (0.50) | P2RX3SCN9ARAF1GRM5 | |
| SCHEMBL29757280 | 0.85 | USP2 (0.50) | P2RX3SCN9ARAF1GRM5 | |
| SCHEMBL6273015 | 0.84 | RAF1 (0.50) | P2RX3RAF1HRH3 | |
| SCHEMBL23900111 | 0.84 | HRH3 (0.50) | P2RX3RAF1HRH3GRM5 | |
| SCHEMBL257959 | 0.84 | RAF1 (0.50) | P2RX3RAF1 | |
| SCHEMBL4155509 | 0.84 | PARP10 (0.51) | RAF1HRH3GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584758-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210317135-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584758-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | P2RX3 3426/4885SCN9A 3587/4885RAF1 60/4885 |
| US-20210317135-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | P2RX3 3426/4885SCN9A 3587/4885RAF1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.